Zymeworks
company
ZYME NYSE
ISIN US98985Y1082 SEC CIK 1937653 LEI 894500AHOYAGYLYZJL67
Follow Zymeworks
Weekly email: filings, results
Revenue, last quarter
$256.5M
+828.7% vs same quarter last year
Net income
$173.7M
+986.1% vs same quarter last year
EPS, diluted
$2.28
+976.9% vs same quarter last year
Operating cash flow
−$24M
+23.5% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $106M | −$81.1M |
| FY24 | $76.3M | −$122.7M |
| FY23 | $76M | −$118.7M |
| FY22 | $412.5M | $124.3M |
| FY21 | $26.7M | −$211.8M |
| FY20 | $39M | −$180.6M |
| FY19 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −87.3% | −76.6% |
| FY24 | −179.7% | −160.8% |
| FY23 | −181.6% | −156.1% |
| FY22 | 31.6% | 30.1% |
| FY21 | −808.2% | −794% |
| FY20 | −481.3% | −463.5% |
| FY19 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$34.5M |
| FY24 | −$112M |
| FY23 | −$120.8M |
| FY22 | $136M |
| FY21 | −$204.9M |
| FY20 | −$155.7M |
| FY19 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $41.7M |
| FY24 | $30.1M |
| FY23 | $0 |
| FY22 | $0 |
| FY21 | - |
| FY20 | - |
| FY19 | - |
- Zymeworks
- Healthcare median
Show the numbers
| Year | Zymeworks | Healthcare median |
|---|---|---|
| FY25 | −76.6% | −30.6% |
| FY24 | −160.8% | −47% |
| FY23 | −156.1% | −58% |
| FY22 | 30.1% | −80.4% |
| FY21 | −794% | −71.9% |
| FY20 | −463.5% | −62.2% |
| FY19 | - | −46.3% |